Exposure to volatile organic compounds and airway inflammation

Jae-Woo Kwon1,2,3*, Hee-Won Park4, Woo Jin Kim2,3, Man-Goo Kim5 and Seung-Joon Lee2,3

Abstract

Background: Exposure to low levels of volatile organic compounds (VOCs) in ordinary life is suspected to be related to oxidative stress and decreased lung function. This study evaluated whether exposure to ambient VOCs in indoor air affects airway inflammation.

Methods: Thirty-four subjects from the hospital that had moved to a new building were enrolled. Symptoms of sick building syndrome, pulmonary function tests, and fractional exhaled nitric oxide (FeNO) were evaluated, and random urine samples were collected 1 week before and after the move. Urine samples were analyzed for VOC metabolites, oxidative stress biomarkers, and urinary leukotriene E4 (uLTE4) levels.

Results: The level of indoor VOCs in the new building was higher than that in the old building. Symptoms of eye dryness and eye irritation, as well as the level of a xylene metabolite (o-methylhippuric acid) increased after moving into the new building (p = 0.012, p = 0.008, and p < 0.0001, respectively). For the inflammatory markers, FeNO decreased (p = 0.012 and p = 0.04, respectively) and the uLTE4 level increased (p = 0.005) after the move.

Conclusion: Exposure to a higher level of VOCs in everyday life could affect airway inflammation.

Keywords: Volatile organic compounds, Sick building syndrome, Oxidative stress, Inflammation, Spirometry

Background

Indoor air pollution is attracting attention as people spend more time indoors. Volatile organic compounds (VOCs) are important indoor air pollutants produced by evaporation at room temperature from diverse sources, such as building materials, paints, cleaning agents, furnishings, adhesives, combustion materials, floor, and wall coverings [1]. Greater use of VOC-containing products, more effective insulation, and less external ventilation of modern buildings has contributed to increased VOC exposure. VOCs are known to be associated with respiratory symptoms in industrial or occupational environments [2], but the effects of exposure to low concentrations on the airway in the general indoor environments of daily life are not clear.

Sick building syndrome (SBS) is associated with various health problems that patients may report with an unclear cause, but with a possible relationship to the indoor environment [3]. However, the causal relationship between SBS and the indoor environment was debated until Lu et al. reported the relationship between exposure to VOCs, SBS symptoms, and oxidative stress among office workers [4]. Yoon et al. showed that urinary levels of VOC metabolites are related with oxidative stress and decreased lung function [5]. However, the mechanism of how VOCs and oxidative stress are related to decreased lung function is unclear. No studies have been performed on airway inflammation induced by exposure to VOCs during ordinary life, and longitudinal studies about SBS are rare, although there are a large number of cross-sectional studies [6].

We hypothesized that exposure to VOCs promotes airway inflammation. We evaluated SBS symptoms, urinary levels of VOC metabolites and oxidative stress markers, lung function, and inflammatory markers including fractional exhaled nitric oxide (FeNO) and urine leukotriene E4 (uLTE4) of subjects before and after
moving into a new building with a relatively high level of ambient VOCs.

**Methods**

**Study subjects**

Study populations were enrolled from the inpatients, caregivers, and workers at a 60-bed rehabilitation hospital that moved to a new building. This is a hospital for patients in daily physical rehabilitation programs and without acute or chronic severe illness. Inclusion criteria were staying in the hospital > 8 h/day for more than 1 week. Exclusion criteria were symptoms of upper respiratory infection within 1 week and any illness that could affect airway inflammation and lung function. The move-in building was newly built and located near the old building within a 900 m straight line, and thus the new building shared almost the same outdoor environment. The old building was located 70 m from a two-lane low-traffic road, whereas the new building was located 200 m from a four-lane low-traffic road.

Demographic characteristics, smoking status, history of allergic diseases, including asthma, allergic rhinitis, atopic dermatitis, food allergy, and drug allergy, and a family history of allergic diseases, were collected. SBS symptoms, lung function tests, and FeNO were evaluated, and spot urine samples were collected 7 days before and after the move (Fig. 1). SBS symptoms included a runny nose, stuffy nose, sneezing, headache, eye dryness, eye irritation, tiredness, skin dryness, chest discomfort, breathing difficulties, sputum, cough, hypersensitivity to pollutions or irritants, wheezing, and any sleeping difficulties [4], and symptoms were evaluated via a visual analogue scale written on a paper questionnaire. FeNO, usually regarded as marker of T-helper cell type 2 (Th2) airway inflammation, was measured using a Niox Mino (Aerocrine, Solna, Sweden) according to American Thoracic Society/European Respiratory Society recommendations by one experienced operator [7]. Spirometry was performed using an Easy One kit (NDD; Zurich, Switzerland), as recommended by the American Thoracic Society/European Respiratory Society [8]. Spot urine samples were collected from all subjects in the afternoon of each day.Skin-prick tests were performed for 15 common inhalant allergens 7 days after the move using a test kit that included a battery of 15 common inhalant allergens (Allergopharma)
and o-, m-, and p-xylenes, respectively [9]. Mandelic were measured as major metabolites of toluene, benzene, m-, and p-methylhippuric acids (o-, m- and p-MHAs) Hippuric acid (HA), tt-muconic acid (tt-MA), and o-, biomarkers Urinary levels of VOC metabolites and oxidative stress Analysis of urine sample ing to the ISO 16000 –lyzed by high performance liquid chromatography accord-
method. Duplicate aldehyde samples were collected on –raphy/mass spectroscopy according to the ISO 16000 –raphy of VOCs and aldehydes were simultaneously with four sampling lines. Duplicate VOC sampling was done by collecting VOCs and aldehydes opening the doors for storing furniture in the room. Air for 1 h by closing the windows and doors of the room but ing the windows and doors to the room and then sealed –sion room. The room was ventilated for 30 min by open-
A total of 34 people were enrolled before the move and were followed for 7 days after the move. The demographic characteristics of the study population are shown in Table 1. There were 11 workers, 14 caregivers, and 9 patients who had been admitted to the hospital for the daily rehabilitation program but had no acute or severe chronic illness. The levels of ambient VOCs were higher in the new building than those in the old building (Table 2). No large differences in daily mean temperature or air

| Age, median (range)  | 57 (27–70) |
| Sex, male no. (%)    | 23 (67.6)  |
| BMI (range)          | 26.0 (20.3–32.9) |
| Indoor stay time (hours) | 24 (8–24) | 
| Allergy Hx, no. (%)  | 9 (26.5)   |
| Allergy F.Hx.        | 11 (32.4)  |
| Atopy. no. (%)a      | 10 (32.3%) |
| Smoking, no. (%)     | 23 (67.6%) |
| Former               | 8 (23.5%)  |
| Current              | 3 (8.8%)   |

*For the 31 patients who were available for atopy tests
pollution were observed before or after the move (Additional file 1: Table S1).

The severity of eye dryness and eye irritation increased \( (p = 0.012 \) and \( p = 0.008 \), respectively), otherwise there were no changes in the severity of other symptoms. The urinary levels of tt-MA decreased after the move \( (p = 0.012; \) Table 3; Fig. 2). In contrast, the levels of o-MHA, m-MHA, and p-MHA increased \( (p < 0.0001, \ p = 0.002, \ p < 0.0001; \) Fig. 2). No changes were observed in the levels of the other VOC metabolites or oxidative stress markers before or after the move. No differences in the changes in the urinary markers were observed according to the eye symptoms after moving or based on a history of allergic diseases or the presence of atopy.

FeNO decreased after the move \( (p = 0.04) \) and the levels of uLTE4 and uLTE4/FeNO increased \( (p = 0.005 \) and \( p = 0.04, \) respectively; Fig. 2). Although no changes in lung function were detected before and after the move (Table 3), the changes in FeNO were negatively correlated with the changes in forced expiratory volume in 1 s (FEV1) \( (L) \) and FEV1 \( (\%) \) \( (r = -0.376, \ p = 0.037 \) and \( r = -0.505, \ p = 0.004, \) respectively; Additional file 1: Figure S1), and with the changes in forced vital capacity (FVC) \( (L) \) and FVC \( (\%) \) before and after the move \( (r = -0.387, \ p = 0.032 \) and \( r = -0.407, \ p = 0.023, \) respectively; Additional file 1: Figure S1). However, no significant correlations were observed among the changes in urinary levels of VOC metabolites, oxidative stress markers, changes in the inflammation markers, including uLTE4, or the lung function tests.

**Discussion**

This study showed changes in inflammatory markers before and after a move into a new building that had higher levels of ambient VOCs and formaldehyde. Decreased FeNO and an increase in uLTE4 after the move suggested changes in the inflammatory environment of the airway, possibly increased non-Th2 inflammation.

Some patients with asthma insist that their respiratory symptoms become aggravated after they move into a new house and point to the new indoor environment as a trigger of their symptoms. Actually, several studies have linked VOC exposure to asthma and other respiratory symptoms, although there is no consistent association between the total concentration of VOCs and SBS [1]. Nocturnal breathlessness in the general population is related to indoor concentrations of formaldehyde and VOCs [12]. VOC exposure and airway infections in infants are correlated [13]. A cross-sectional observation study reported the relationship among urinary levels of VOC metabolites, oxidative stress, and decreased lung function [5]. However, there is a lack of evidence for the direct effects of VOC exposure and changes in lung physiology in humans. This longitudinal study showed that 7-day exposure to ambient VOCs in daily life affected airway inflammation and possibly lung mechanics in the general population.

The FeNO measurement is used to assess the degree of Th2 allergic inflammation in the airway [14]. Decreased levels of FeNO after the move suggested a decreased level of Th2 inflammation in the airway and may suggest a relative increase in non-Th2 inflammation in the airway with increased uLTE4. Nitric oxide (NO) is present in all mammalian organs and is one of the endogenous regulators in physiological conditions such as vasodilation and bronchodilation. NO increases during acute and chronic inflammation as an important inflammatory mediator [15–17]. NO in expired air is produced in bronchial epithelial cells by nitric oxide synthase (NOS)2, which increases in response to inflammation, and is thought to indirectly reflect airway inflammation [18]. Exhaled NO is associated with eosinophilic inflammation in the airway and is significantly correlated with eosinophil cationic protein and eosinophil counts in an airway mucosal biopsy and bronchial lavage of patients with asthma [19−21]. In the current study, the changes in FeNO were negatively correlated with the changes in FEV1 and FVC after the move, although no significant changes in lung functions were observed before or after the move. These results suggest that exposure to a higher dose of ambient VOCs during ordinary life inflamed the airway and induced changes in lung dynamics.

ulTE4 is a biomarker for assessing changes in the rate of total body cysteinyl leukotriene levels. Leukotrienes are a family of lipid mediators derived from arachidonic acid through the 5-lipoxygenase pathway that are produced by various leukocytes [10], and induce bronchoconstriction of the airway [22]. Approximately 5% of airway cysteinyl leukotrienes are eventually eliminated in the urine, and almost all in the form of uLTE4 [23]. Piedimonte et al. reported that uLTE4 was eight-fold higher in infants with bronchiolitis than in controls [24]. Among patients with asthma, uLTE4 is a biomarker of

---

**Table 2 Ambient levels of volatile organic compounds (VOCs) in the old and new buildings**

| VOCs (μg/m³) | Old building | New building |
|-------------|--------------|--------------|
| TVOC        | 119          | 1054         |
| SVOC        | Benzene      | 0.86         | 41.94        |
|             | Toluene      | 13.5         | 235.15       |
|             | Ethylbenzene | 0.36         | 1.54         |
|             | m, p Xylene  | 0.68         | 5.8          |
|             | Styrene      | 0.38         | 1.15         |
|             | o-Xylene     | 0.25         | 2.56         |
| Formaldehyde| 18.65        | 90.67        |
| Acetaldehyde| 3.8          | 12.99        |
exposure to asthma triggers, such as air pollution and second-hand smoke, and is regarded as an important mediator of asthma exacerbation [10]. In addition, a high ratio of uLTE4 to FeNO (uLTE4/FeNO) seems to indicate predominantly non-Th2 airway inflammation [10]. Thus, increases in uLTE4 and uLTE4/FeNO in the current study suggest an increase in non-Th2 inflammation in the airway of the study population after moving into the new building.

Several studies have investigated human exposure to VOCs [25, 26]. These studies conducted short-term (2–4 h) exposure with 25–50 times higher (25–50 mg/m³) concentrations of VOCs and there were no changes in lung function or inflammatory markers, such as inflammatory cell profiles in nasal lavage and induced sputum, or biomarkers of airway inflammation, including LTB4 [26]. Short-term exposure to four types of VOCs in a mixture (formaldehyde, benzene, toluene, and xylene) induces NOS activity and the NO signaling pathway in mice [32]. However, the current study showed that 7-day exposure to a low concentration of VOCs (1 mg/m³ total VOCs) in daily life decreased FeNO and increased uLTE4 in the normal population, suggesting increased non-Th2 inflammation in the airway. Differences between results of animal studies and the current study may have originated from differences in the concentration and duration of exposed VOCs and differences between mice and humans.

Yoon et al. showed that urinary levels of HA and MHA are associated with reduced lung function and that VOC metabolites are related with oxidative stress [5]. Toluene, o-, m-, and p-xylens, styrene, and ethylbenzene are widely used as organic solvents in the plastic, rubber, and pharmaceutical industries. Major metabolites of these VOCs are HA, o-, m-, and p-MHAs, MA, and PGA, and their urinary concentrations have been used to biologically

Table 3 Changes in lung function, inflammatory markers, and biochemical analyses

|                          | Before move (n = 34) | After move (n = 34) | p-value |
|--------------------------|---------------------|---------------------|--------|
| Lung function testsa     |                     |                     |        |
| FEV1, L                  | 2.51 (0.69–4.05)    | 2.44 (1.39–3.96)    | 0.688  |
| FEV1, %                  | 90 (30–119)         | 93 (64–118)         | 0.410  |
| FVC, L                   | 3.14 (1.01–5.06)    | 3.03 (1.82–5.19)    | 0.688  |
| FVC, %                   | 90 (33–118)         | 91 (70–111)         | 0.448  |
| FEV1/FVC                 | 80 (65–89)          | 80 (67–90)          | 0.734  |
| FEV25–75, L/s            | 2.71 (0.39–6.08)    | 2.57 (0.72–4.95)    | 0.899  |
| FEV25–75, %              | 90 (19–168)         | 94 (33–190)         | 0.959  |
| FeNO (ppm)               | 21 (11–43)          | 19 (7–44)           | 0.040  |
| uLTE4 (pg/ml)            | 252.4 (36.8–5889.5) | 460.6 (150.0–5570.9)| 0.005  |
| FeNO / uLTE4             | 11.1 (1.2–145.4)    | 20.7 (0.7–206.3)    | 0.004  |
| Oxidative stress biomarkers |                   |                     |        |
| MDA (μmol/g Cr.)         | 1.3 (0.4–8.8)       | 1.4 (0.4–3.3)       | 0.578  |
| 8-OHdG (ng/mg Cr.)       | 3.4 (0.6–8.2)       | 3.0 (0.3–8.3)       | 0.351  |
| VOC metabolites          |                     |                     |        |
| t,t-MA (μg/g Cr)         | 85.8 (30.2–623.8)   | 68.0 (9.5–347.0)    | 0.012  |
| HA (mg/g Cr)             | 204.4 (8.6–1984.9)  | 272.9 (180.0–1978.1)| 0.714  |
| MA (μg/g Cr)             | 183.5 (68.7–440.6)  | 215.1 (71.3–2481.6)| 0.118  |
| PGA (μg/g Cr)            | 47.4 (4.9–431.6)    | 63.4 (3.9–431.8)    | 0.966  |
| o-MHA (μg/g Cr)          | 60.7 (12.2–307.0)   | 99.7 (30.3–299.6)   | 0.000  |
| m-MHA (μg/g Cr)          | 101.7 (25.9–912.2)  | 164.6 (80.4–453.6)  | 0.002  |
| p-MHA (μg/g Cr)          | 52.4 (17.5–401.3)   | 88.6 (30.2–630.9)   | 0.000  |

*Median (range)
† Sputum eosinophilia, eosinophil ≥3% in induced sputum
AR allergic rhinitis
Bold typeface indicates P < 0.05
monitor occupational exposure to these VOCs [9]. The level of urinary MHA increased 7 days after moving into the new building. However, the level of urinary tt-MA decreased despite the move to a new indoor environment with higher ambient benzene. The reason for the decreased levels of urinary tt-MA is not clear but the absence of an association between the level of ambient benzene and urinary tt-MA was observed in a previous study [5]. About 2% of the total benzene taken up by humans is excreted via urine as tt-MA, and its excretion half-life is <6 h [33]. Although urinary tt-MA has been recommended as a biomarker to assess occupational exposure to benzene, Jalai et al. showed that tt-MA cannot be used as a reliable biomarker for exposure to low dose benzene [34].

This study had several limitations that should be discussed. First, there were no direct evaluations of airway inflammation. Accessing airway inflammation is difficult, as most of the tools, including bronchoscopy and induced sputum, are invasive and require additional special support. Thus, several indirect methods used to evaluate airway inflammation have been tried. FeNO is a successful and commonly used method to access airway inflammation. uLTE4 is a laboratory tool used to access airway inflammation. uLTE4 is a laboratory tool used to access airway inflammation. Gaki et al. 2007; Hallstrand and Henderson 2010; Kumlin et al. 1992; Pappas et al. 2000; Piedimonte et al. 2005; Rabinovitch 2012). Second, there could be many other variables that changed during the move into a new building, and the ambient levels of indoor VOCs constitute one of them. However, the outdoor environment was suspected to be similar before and after the move, as the distance between the new and old hospital was close, and the new hospital was located farther from the traffic. In addition, there were no large differences in temperature or air pollution around each evaluation date before and after the move. The move-in building was newly built, and both the old and new buildings had a similar structure as hospital buildings, with complete separation from secondary cooking products. In addition, personal factors, including age, smoking, medication, and weekly lifestyle, might be adjusted, as the same person was evaluated before and after the move at a similar time of day with a 14-day gap. Thus, changes before and after the move were suspected to be relatively limited to changes in the indoor environment, and exposure to higher levels of indoor VOCs were one of the main changes.

**Conclusions**

Although VOCs in ordinary indoor environments are associated with respiratory symptoms, oxidative stress, and decreased lung function, no longitudinal study has shown the effects of VOC exposure to the airway in ordinary indoor environments. For the first time, this study...
showed that 7-day VOC exposure during ordinary life can affect airway inflammation, possibly non-Th2 inflammation.

Additional file

Additional file 1. Table S1. Outdoor environment over the 6 days before and at each evaluation date before and after the move. Figure S1. Correlation between changes in fractional exhaled nitric oxide (FeNO) and lung function tests before and after the move. (DOCX 62 kb)

Abbreviations

8-OHdG: 8-oxo-2′-deoxyguanosine; FeNO: Fractional exhaled nitric oxide; HA: Hippuric acid; MA: Mandelic acid; MDA: Malondialdehyde; o-, m- and p-MHAs: o-, m- and p-methylhippuric acids; PGA: Phenylglyoxylic acid; SBS: Sick building syndrome; TH2: T-helper cell type 2; tt-MA: t-tartaric acid; uLTE4: Urinary leukotriene E4; VAS: Visual analogue scale; VOC: Volatile organic compounds

Availability of data and materials

All data generated or analyzed during this study are included in this published article and the references in the current study.

Authors’ contributions

Jae-Woo Kwon conceived the study, designed the survey, and oversaw the data collection and analysis. Hee-Won Park and Seung-Joon Lee helped the data collection and analysis. Hee-Won Park and Seung-Joon Lee helped in the revising of the manuscript and approved the final version.

Ethics approval

All of the study population signed written informed consent forms and participation of human subjects did not occur until after informed consent was obtained. All the study procedures and the participants were in accordance with the Declaration of Helsinki (1964) and its later amendments.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Allergy and Clinical Immunology, Kangwon National University Hospital, Chuncheon, South Korea. 2Department of Internal Medicine, Kangwon National University College of Medicine, Baengnyeong-ro 256, 200-722 Chuncheon-Si, Gangwon-do, Chuncheon, South Korea. 3Environmental Health Center, Kangwon National University Hospital, Chuncheon, South Korea. 4Department of Rehabilitation Medicine, Kangwon National University College of Medicine, Chuncheon, South Korea. 5Department of Environmental Science, Kangwon National University, Chuncheon, South Korea.

Received: 20 March 2018 Accepted: 26 July 2018

Published online: 07 August 2018

References

1. Numatov I, Išk, Tagiyeva N, Sempie S, Devereux G, Sheikh A. Volatile organic compounds and risk of asthma and allergy: a systematic review. Eur Respir Rev. 2015;24:92–101.
2. Jang AS, Choi IS, Koh YI, Park CS. Volatile organic compounds contribute to airway hyperresponsiveness. Korean J Intern Med. 2007;22:8–12.
3. Norback D. An update on sick building syndrome. Curr Opin Allergy Clin Immunol. 2009;9:55–9.
4. Lu CY, Ma YC, Lin JM, Li CY, Lin RS, Sung FC. Oxidative stress associated with indoor air pollution and sick building syndrome-related symptoms among office workers in Taiwan. Inhal Toxicol. 2007;19:57–65.
5. Yoon HI, Hong YC, Cho SH, Kim H, Kim VH, Sohn JR, et al. Exposure to volatile organic compounds and loss of pulmonary function in the elderly. Eur Respir J. 2010;36:1270–7.
6. Apter A, Bracker A, Hodgson M, Sidman J, Leung WY. Epidemiology of the sick building syndrome. J Allergy Clin Immunol. 1994;94:277–88.
7. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912–30.
8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.
9. Ohashi Y, Mamiya T, Miyata K, Wang BL, Takigawa T, Kira S, et al. Simultaneous determination of urinary hippuric acid, o-, m- and p-methylhippuric acids, mandelic acid and phenylglyoxylic acid for biomonitoring of volatile organic compounds by gas chromatography-mass spectrometry. Anal Chim Acta. 2006;566:67–71.
10. Rabinovitch N. Urinary leukotriene E4 as a biomarker of exposure, susceptibility and risk in asthma. Immunol Allerg Clin N Am. 2012;32:433–45.
11. Gaki E, Papatheodorou G, Ischaki E, Grammenou V, Papa I, Loukides S. Leukotriene E(4) in urine in patients with asthma and COPD—the effect of smoking habit. Respir Med. 2007;101:826–32.
12. Norback D, Bjornsson E, Janson C, Widstrom J, Roman G. Asthmatic symptoms and volatile organic compounds, formaldehyde, and carbon dioxide in dwellings. Occup Environ Med. 1995;52:388–95.
13. Deiz U, Krosnzer S, Rehwagen M, Richter M, Wetzig H, Schulz R, et al. Effects of indoor painting and smoking on airway symptoms in atop allergic children in the first year of life results of the LARS-study. Leipzig allergy high-risk children study. Int J Hyg Environ Health. 2000;203:23–8.
14. Dweik RA, Boggs PG, Erzumac GM, Irving CG, Lewis MW, Lundborg JG, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–15.
15. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78:195–8.
16. Kim SH, Yoon HJ. Use of the exhaled nitric oxide for management of asthma and respiratory diseases. Korean J Med. 2008;74:579–86.
17. Morris SM Jr, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Ann J Phys. 1994;266:E829–39.
18. Guo FH, Comhair SA, Zheng S, Dweik RA, Essa NT, Thomsassen MJ, et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol. 2000;164:5970–80.
19. Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax. 2002;57:383–7.
20. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med. 2001;164:1376–81.
21. Berry MA, Shaw DE, Green RH, Brighthel CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy. 2005;35:1175–9.
22. Hallstrand TS, Henderson WR Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010;10:60–6.
23. Kumlin M, Dahlén B, Björck T, Zetterström O, Granström E, Dahlén SE. Urinary excretion of leukotriene E4 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis. 1992;146:964–70.
24. Piedimonte G, Renzetti G, Auais A, Di Marco A, Tripodi S, Cistola F, et al. Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. Pediatr Pulmonol. 2005;40:285–91.
25. Fedler N, Laumbach R, Kelly-McNeil K, Lioy P, Fan ZH, Zhang J, et al. Health effects of a mixture of indoor air volatile organics, their ozone oxidation products, and stress. Environ Health Perspect. 2005;113:1542–8.
26. Pappas GP, Herbert RJ, Henderson W, Koenig J, Stover B, Barnhart S. The respiratory effects of volatile organic compounds. Int J Occup Environ Health. 2000;6:1–8.

27. Ban M, Langonne I, Huguet N, Pepin E, Morel G. Inhaled chemicals may enhance allergic airway inflammation in ovalbumin-sensitised mice. Toxicology. 2006;226:161–71.

28. Fujimaki H, Yamamoto S, Tin Tin Win S, Hojo R, Sato F, Kunugita N, et al. Effect of long-term exposure to low-level toluene on airway inflammatory response in mice. Toxicol Lett. 2007;168:132–9.

29. Tin Tin Win S, Yamamoto S, Nakajima D, Furuyama A, Fukushima A, Ahmed S, et al. Modulation of neurological related allergic reaction in mice exposed to low-level toluene. Toxicol Appl Pharmacol. 2007;222:17–24.

30. Bechtel DG, Waldner CL, Wickstrom M. Associations between in utero exposure to airborne emissions from oil and gas production and processing facilities and immune system outcomes in neonatal beef calves. Arch Environ Occup Health. 2009;64:59–71.

31. Wang F, Li C, Liu W, Jin Y, Guo L. Effects of subchronic exposure to low-dose volatile organic compounds on lung inflammation in mice. Environ Toxicol. 2014;29:1089–97.

32. Wang F, Li C, Liu W, Jin Y. Effect of exposure to volatile organic compounds (VOCs) on airway inflammatory response in mice. J Toxicol Sci. 2012;37:739–48.

33. Inoue O, Seiji K, Nakatsuka H, Watanabe T, Yin SN, Li GL, et al. Urinary t,t-muconic acid as an indicator of exposure to benzene. Br J Ind Med. 1989;46:122–7.

34. Jalai A, Ramezani Z, Ebrahim K. Urinary trans, trans-Muconic acid is not a reliable biomarker for low-level environmental and occupational benzene exposures. Saf Health Work. 2017;8:220–5.